Advanced Dialysis Solutions for Chronic Kidney Disease: Icodextrin-based Peritoneal Dialysis Solutio
公開 2026/03/27 18:07
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Icodextrin-based Peritoneal Dialysis Solution - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Icodextrin-based Peritoneal Dialysis Solution market, including market size, share, demand, industry development status, and forecasts for the next few years.
For patients with end-stage renal disease (ESRD) undergoing peritoneal dialysis, maintaining adequate fluid removal and solute clearance during extended dwell periods presents significant clinical challenges. Traditional glucose-based dialysates are rapidly absorbed during long dwells, reducing their osmotic gradient and limiting ultrafiltration—particularly problematic for patients with high-average or high peritoneal transport status. Icodextrin-based peritoneal dialysis solution addresses this challenge with a dialysate designed for continuous ambulatory peritoneal dialysis (CAPD), used as a single long-dwell daily exchange with a dwell time of 8 to 16 hours. This formulation, suitable for patients with high-average or high peritoneal transport status as assessed by the peritoneal equilibration test (PET), provides enhanced long-dwell ultrafiltration and improved creatinine and blood urea nitrogen clearance. The global market for icodextrin-based peritoneal dialysis solution was valued at US$ 89.1 million in 2025 and is projected to grow at a CAGR of 8.1% to reach US$ 153 million by 2032, driven by increasing prevalence of end-stage renal disease, growing adoption of peritoneal dialysis as home-based therapy, and expanding awareness of the benefits of icodextrin for long-dwell exchanges. In 2024, global sales volume is projected to reach 6.63 million units, with an average price of US$ 12.5 per unit.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097358/icodextrin-based-peritoneal-dialysis-solution
Market Definition and Product Segmentation
Icodextrin-based peritoneal dialysis solution represents a specialized category within the renal replacement therapy market, distinguished by its use of icodextrin—a glucose polymer—as the osmotic agent instead of conventional glucose. This formulation provides sustained ultrafiltration over extended dwell times, making it particularly valuable for the long-daily exchange in CAPD regimens.
Volume Segmentation
The market is stratified by bag volume, each addressing distinct prescription requirements:
2 L: The dominant segment for standard CAPD prescriptions, providing sufficient volume for adult patients undergoing long-dwell exchange.
2.5 L: The higher-volume segment for patients requiring larger fill volumes based on body size, peritoneal transport characteristics, or clinical requirements.
Application Segmentation
The market serves critical renal care settings:
Hospital: The largest segment, encompassing inpatient dialysis units, nephrology departments, and hospital-based renal care programs.
Dialysis Center: Serving outpatient dialysis facilities and specialized renal care centers.
Clinic: Including nephrology clinics and ambulatory care settings where patients receive dialysis therapy and monitoring.
Competitive Landscape
The icodextrin-based peritoneal dialysis solution market features a concentrated competitive landscape dominated by specialized renal care manufacturers. Key players include Baxter, Vantive, and Pharmasyntez Group.
Industry Development Characteristics
1. Enhanced Long-Dwell Ultrafiltration
A case study from QYResearch's industry monitoring reveals that icodextrin provides superior ultrafiltration during extended dwell times compared to conventional glucose-based solutions. Glucose is rapidly absorbed from the peritoneal cavity, reducing osmotic gradient within hours; icodextrin, as a large glucose polymer, remains in the peritoneal cavity longer, maintaining osmotic gradient and fluid removal throughout the 8-16 hour dwell.
2. High-Transport Patient Benefit
Patients with high-average or high peritoneal transport status—who absorb glucose rapidly—are particularly at risk for inadequate ultrafiltration with conventional solutions. A case study from the nephrology sector indicates that icodextrin-based solutions provide consistent ultrafiltration in these patients, reducing fluid overload and improving clinical outcomes.
3. Home Dialysis Expansion
The shift toward home-based dialysis—enabled by patient preference, improved training programs, and healthcare cost considerations—has increased adoption of peritoneal dialysis. A case study from the healthcare delivery sector indicates that icodextrin-based solutions, used for the long-daily exchange in CAPD, are essential components of successful home dialysis programs.
4. Clinical Outcomes and Quality of Life
Icodextrin-based solutions have demonstrated clinical benefits beyond ultrafiltration, including improved sodium removal, better blood pressure control, and reduced risk of ultrafiltration failure. A case study from the clinical nephrology literature indicates that these benefits contribute to improved patient outcomes and quality of life.
Exclusive Industry Insights: The Mechanical Function Advantage
Our proprietary analysis identifies the mechanical mechanism of icodextrin as the key differentiator from conventional glucose-based solutions. Rather than relying on rapid absorption for osmotic effect, icodextrin creates sustained colloidal osmotic pressure—similar to how albumin maintains intravascular volume—providing consistent fluid removal throughout the dwell period. This sustained ultrafiltration reduces the need for fluid restriction, improves blood pressure control, and extends technique survival for patients on peritoneal dialysis.
Strategic Outlook
For industry executives, investors, and marketing leaders evaluating opportunities in the icodextrin-based peritoneal dialysis solution market, the projected 8.1% CAGR reflects sustained demand from growing ESRD prevalence, expanding home dialysis adoption, and increasing recognition of icodextrin's clinical benefits. Manufacturers positioned to capture disproportionate share share three characteristics: demonstrated expertise in sterile pharmaceutical manufacturing and renal therapy products; product portfolios spanning multiple volume configurations; and established relationships with nephrology departments, dialysis centers, and home dialysis programs. As the market evolves toward integrated renal care management, the ability to deliver reliable, clinically effective dialysis solutions will define competitive leadership.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
For patients with end-stage renal disease (ESRD) undergoing peritoneal dialysis, maintaining adequate fluid removal and solute clearance during extended dwell periods presents significant clinical challenges. Traditional glucose-based dialysates are rapidly absorbed during long dwells, reducing their osmotic gradient and limiting ultrafiltration—particularly problematic for patients with high-average or high peritoneal transport status. Icodextrin-based peritoneal dialysis solution addresses this challenge with a dialysate designed for continuous ambulatory peritoneal dialysis (CAPD), used as a single long-dwell daily exchange with a dwell time of 8 to 16 hours. This formulation, suitable for patients with high-average or high peritoneal transport status as assessed by the peritoneal equilibration test (PET), provides enhanced long-dwell ultrafiltration and improved creatinine and blood urea nitrogen clearance. The global market for icodextrin-based peritoneal dialysis solution was valued at US$ 89.1 million in 2025 and is projected to grow at a CAGR of 8.1% to reach US$ 153 million by 2032, driven by increasing prevalence of end-stage renal disease, growing adoption of peritoneal dialysis as home-based therapy, and expanding awareness of the benefits of icodextrin for long-dwell exchanges. In 2024, global sales volume is projected to reach 6.63 million units, with an average price of US$ 12.5 per unit.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097358/icodextrin-based-peritoneal-dialysis-solution
Market Definition and Product Segmentation
Icodextrin-based peritoneal dialysis solution represents a specialized category within the renal replacement therapy market, distinguished by its use of icodextrin—a glucose polymer—as the osmotic agent instead of conventional glucose. This formulation provides sustained ultrafiltration over extended dwell times, making it particularly valuable for the long-daily exchange in CAPD regimens.
Volume Segmentation
The market is stratified by bag volume, each addressing distinct prescription requirements:
2 L: The dominant segment for standard CAPD prescriptions, providing sufficient volume for adult patients undergoing long-dwell exchange.
2.5 L: The higher-volume segment for patients requiring larger fill volumes based on body size, peritoneal transport characteristics, or clinical requirements.
Application Segmentation
The market serves critical renal care settings:
Hospital: The largest segment, encompassing inpatient dialysis units, nephrology departments, and hospital-based renal care programs.
Dialysis Center: Serving outpatient dialysis facilities and specialized renal care centers.
Clinic: Including nephrology clinics and ambulatory care settings where patients receive dialysis therapy and monitoring.
Competitive Landscape
The icodextrin-based peritoneal dialysis solution market features a concentrated competitive landscape dominated by specialized renal care manufacturers. Key players include Baxter, Vantive, and Pharmasyntez Group.
Industry Development Characteristics
1. Enhanced Long-Dwell Ultrafiltration
A case study from QYResearch's industry monitoring reveals that icodextrin provides superior ultrafiltration during extended dwell times compared to conventional glucose-based solutions. Glucose is rapidly absorbed from the peritoneal cavity, reducing osmotic gradient within hours; icodextrin, as a large glucose polymer, remains in the peritoneal cavity longer, maintaining osmotic gradient and fluid removal throughout the 8-16 hour dwell.
2. High-Transport Patient Benefit
Patients with high-average or high peritoneal transport status—who absorb glucose rapidly—are particularly at risk for inadequate ultrafiltration with conventional solutions. A case study from the nephrology sector indicates that icodextrin-based solutions provide consistent ultrafiltration in these patients, reducing fluid overload and improving clinical outcomes.
3. Home Dialysis Expansion
The shift toward home-based dialysis—enabled by patient preference, improved training programs, and healthcare cost considerations—has increased adoption of peritoneal dialysis. A case study from the healthcare delivery sector indicates that icodextrin-based solutions, used for the long-daily exchange in CAPD, are essential components of successful home dialysis programs.
4. Clinical Outcomes and Quality of Life
Icodextrin-based solutions have demonstrated clinical benefits beyond ultrafiltration, including improved sodium removal, better blood pressure control, and reduced risk of ultrafiltration failure. A case study from the clinical nephrology literature indicates that these benefits contribute to improved patient outcomes and quality of life.
Exclusive Industry Insights: The Mechanical Function Advantage
Our proprietary analysis identifies the mechanical mechanism of icodextrin as the key differentiator from conventional glucose-based solutions. Rather than relying on rapid absorption for osmotic effect, icodextrin creates sustained colloidal osmotic pressure—similar to how albumin maintains intravascular volume—providing consistent fluid removal throughout the dwell period. This sustained ultrafiltration reduces the need for fluid restriction, improves blood pressure control, and extends technique survival for patients on peritoneal dialysis.
Strategic Outlook
For industry executives, investors, and marketing leaders evaluating opportunities in the icodextrin-based peritoneal dialysis solution market, the projected 8.1% CAGR reflects sustained demand from growing ESRD prevalence, expanding home dialysis adoption, and increasing recognition of icodextrin's clinical benefits. Manufacturers positioned to capture disproportionate share share three characteristics: demonstrated expertise in sterile pharmaceutical manufacturing and renal therapy products; product portfolios spanning multiple volume configurations; and established relationships with nephrology departments, dialysis centers, and home dialysis programs. As the market evolves toward integrated renal care management, the ability to deliver reliable, clinically effective dialysis solutions will define competitive leadership.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ